Santen gains rights to TRACON's entoglin antibodies for eye uses

Save

The Japanese eye care company will pay $10m up front to the private US venture plus undisclosed development and commercialization milestones and tiered royalties on global sales of TRC105, the lead project in the group. It will also cover all development…